PD-1 is concerned with an existing pathway that tumors essentially hijack in order to down-regulate T-cells. Anti-PD1 drugs seek to block this effect, which potentially would enable the body's own immune system to successfully attack a tumor cell.
Fair chance it will prove the most exciting new development in oncology in a while.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.